MYBL2 and cancer: Thirteen out of the 24: UBE2C, ADRM1, CSE1L, RPN2, C20orf45, MYBL2, TOMM34, AURKA, RAE1, PFDN4, PSMA7, RPS21 and VAPB showed exceptionally significant over-expression in several cancers, in progressed malignant stages (versus early) and in poor (compared to good) prognosis samples (see Figure S8 for stage, grade and prognosis and Figure S9 for survival data).